Management of WPW Syndrome with Atrial Fibrillation

Critical Safety Issues

• Beta-blockers like metoprolol are explicitly contraindicated (Class III recommendation) in patients with WPW who have pre-excited ventricular activation during atrial fibrillation, as they can accelerate conduction through the accessory pathway, potentially precipitating ventricular fibrillation and sudden cardiac death, according to the American Heart Association 1
• The mechanism of harm: beta-blockers slow AV nodal conduction but do not affect the accessory pathway, leading to preferential conduction through the bypass tract during AF with potentially fatal rapid ventricular rates, as stated by the American College of Cardiology 1

Immediate Management Algorithm

• Contact the prescribing cardiologist immediately to discuss discontinuation of metoprolol, as recommended by the American Heart Association 1
• Flecainide alone may provide adequate rate control and is appropriate for WPW with AF (Class I recommendation), according to the European Society of Cardiology 3, 1

Definitive WPW Management

• Catheter ablation of the accessory pathway should be strongly considered as first-line definitive treatment, with a success rate of >95% and a complication rate of <1-2% in experienced centers, as recommended by the Heart Rhythm Society 1, 2

Important Clinical Caveats

• The recent AF RVR episode indicates the patient has developed symptomatic arrhythmias, elevating sudden death risk more than 10-fold, according to the American College of Cardiology 1, 4
• Approximately one-third of WPW patients develop atrial fibrillation, which can degenerate into ventricular fibrillation, as stated by the European Society of Cardiology 1

Medications to Avoid

• Beta-blockers (metoprolol), non-dihydropyridine calcium channel blockers (diltiazem, verapamil), digoxin, IV amiodarone during pre-excited AF, and adenosine when QRS is wide should be avoided in this patient, as recommended by the American Heart Association 1, 2

Alternative ADHD Management Options

• The safest approach is to defer ADHD pharmacotherapy until after definitive WPW treatment with catheter ablation, as recommended by the American Academy of Pediatrics 1